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Background: Providers and patients have called for improved understanding of the health care requirements of
adults with sickle cell disease (SCD) and have identified the need for a systematic, reliable and valid method to
document the patient-reported outcomes (PRO) of adult SCD care. To address this need, the Adult Sickle Cell Quality of
Life Measurement System (ASCQ-Me) was designed to complement the Patient Reported Outcome Measurement
Information System (PROMIS®). Here we describe methods and results of the psychometric evaluation of ASCQ-Me item
banks (IBs).
Methods: At seven geographically-disbursed clinics within the US, 556 patients responded to questions generated to
assess cognitive, emotional, physical and social impacts of SCD. We evaluated the construct validity of the hypothesized
domains using exploratory factor analysis (EFA), parallel analysis (PA), and bi-factor analysis (Item Response Theory
Graded Response Model, IRT-GRM). We used IRT-GRM and the Wald method to identify bias in responses across gender
and age. We used IRT and Cronbach’s alpha coefficient to evaluate the reliability of the IBs and then tested the ability
of summary scores based on IRT calibrations to discriminate among tertiles of respondents defined by SCD severity.
Results: Of the original 140 questions tested, we eliminated 48 that either did not form clean factors or provided
biased measurement across subgroups defined by age and gender. Via EFA and PA, we identified three subfactors
within physical impact: sleep, pain and stiffness impacts. Analysis of the resulting six item sets (sleep, pain, stiffness,
cognitive, emotional and social impacts of SCD) supported their essential unidimensionality. With the exception of the
cognitive impact IB, these item sets also were highly reliable across a broad range of values and highly significantly
related to SCD disease severity.
Conclusion: ASCQ-Me pain, sleep, stiffness, emotional and social SCD impact IBs demonstrated exceptional
measurement properties using modern and classical psychometric methods of evaluation. Further development of the
cognitive impact IB is required to improve its sensitivity to differences in SCD disease severity. Future research will
evaluate the sensitivity of the ASCQ-Me IBs to change in SCD disease severity over time due to health interventions.
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Owing to advances in therapy and increased use of pre-
ventative medicine, more than ninety-percent of individ-
uals with sickle cell disease (SCD) now grow out of
pediatric care. However their optimal functioning and
well-being may be compromised by chronic comorbid
conditions including multi-organ failure, pain and neu-
rocognitive deficits [1-3]. Social and economic chal-
lenges are common, as well as barriers to accessing
quality healthcare [1,4]. There is thus a need for skilled
adult-oriented health care providers to deliver sickle cell
care and a corresponding need to improve understand-
ing of the long-term needs of adults with SCD.
Beginning in 2002, the National Heart, Lung and
Blood Institute (NHLBI) conducted a series of confer-
ences and workshops to determine ways to improve
treatment for adults living with SCD [5]. Stakeholders
communicated the need for a systematic, reliable and
valid method for documenting adult patient-reported
outcomes (PRO) of care. We developed the Adult Sickle
Cell Quality of Life Measurement Information System,
or ASCQ-Me (pronounced “Ask me”), to meet this need.
In this article we detail the statistical methods used to
identify the most precise measures to include in ASCQ-
Me item banks and continue this introduction by sum-
marizing the formative research upon which the current
work was based (detailed in Treadwell, Hassell, Levine
and Keller, 2013[6]).
Formation of the conceptual framework for ASCQ-Me
Because the epidemiology and psychosocial functioning
of adults with SCD is understudied and not well-
documented, we conducted a comprehensive program of
formative research including a systematic review of the
literature. We also conducted detailed, structured inter-
views with 123 adults with SCD and 15 sickle cell ex-
perts who varied in geographic location, age and gender.
On the basis of these data, we created an inclusive tax-
onomy of 140 life areas that were affected by SCD and
summarized these in a model of relationships between
the signs and symptoms of SCD and adult life experi-
ences [6].
Grounded item technique (GIT)
We “grounded” ASCQ-Me questions in actual events in
the lives of the interview participants through a rigorous
analytic protocol applied to the audio-taped group or in-
dividual interviews [7,8]. The content based on GIT was
supplemented, when required, by questions based on
legacy measures. For example, SCD providers and clin-
ical investigators advocated for the importance of in-
cluding questions on cognitive functioning as part of
ASCQ-Me; yet no content related to attention, memory,
language or problem solving emerged from the GITinterviews. So we based the draft cognitive functioning
items for ASCQ-Me on the careful, thoroughly docu-
mented work of the Medical Outcomes Study [9].
ASCQ-Me questions were written in plain language
comprehensible at the 6th grade level or below. We
avoided the use of clauses, and restricted the item con-
tent to one topic. To promote standardization, we used
item formats comparable to the cross-National Institutes
of Health (NIH) generic PRO measure development ef-
fort, the Patient-Reported Outcomes Measurement In-
formation System (PROMIS®) [10]. Experts in cognitive
testing from the Cognitive Laboratory at the American
Institutes for Research reviewed all of the items to iden-
tify those that should be rewritten. Those that could not
be rewritten without destroying the intended meaning
were submitted to cognitive testing with patients and, if
they were correctly understood, they were retained
(otherwise they were discarded). The field test version of
ASCQ-Me was based on this set of culled items.
The purpose of the ASCQ-Me field test data collection
was to identify the ASCQ-Me items that would be the
most precise measures of their constructs for inclusion
in item banks suitable for administration using computer
adaptive assessment software, determine appropriate
scoring algorithms for those items, and evaluate the reli-
ability and validity of scores based on those algorithms.
Methods
Participants
ASCQ-Me field test data were collected at seven geo-
graphically diverse sites of care with the assistance of site
coordinators trained in a standardized study protocol.
Four methods were used to recruit participants: some
were invited to participate by personnel at each clinic;
others responded to flyers posted in or near the clinics;
some responded to a posting on the website for the
Sickle Cell Disease Association of America; and still
others were recruited by participants who had already
taken the assessments. Prior to enrollment, potential
participants were administered a short screener. To be
eligible for the data collection, participants were re-
quired to be 18 years of age or older and to be diagnosed
with sickle cell disease. People were excluded if they
were younger than 18, did not have a diagnosis of SCD,
had a diagnosis of sickle cell trait, or could not read
English. Based on previous research findings [11], the tar-
geted enrollment across sites was set to obtain sufficient
sample size for the psychometric analyses (500 patients)
assuming a ten-percent rate of no-shows. Thus we targeted
550 patients with diversity in terms of age and gender.
Measures
Four item sets were developed: cognitive impact (28
items), emotional impact (28 items), social functioning
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addition, five items were developed for fixed format ad-
ministration: pain episode severity (3 items) and frequency
(2 items). Examples of the questions are presented in
Table 1 below.
We sought to include a measure of SCD severity to
evaluate the ability of ASCQ-Me measures to reflect dif-
ferences in groups of people who differed in the extent
of their disease. The challenge for us was that there is
no consensus method for assessing SCD severity. SCD is
characterized by the type of mutations to the pair of
beta-hemoglobin (Hb) genes. Variations include Hb-SS,
Hb-SC and Hb-Sβ [11,12] and individuals with Hb-SS
usually, but not always, have more symptoms than those
with other genotypes [13-15]. The variation of symptoms
and sequelae within genotypes is so broad that genotype
can not serve as a reliable indicator of disease severity
[16-19]. Incidence and frequency of hospitalizations for
vaso-occlusive incidents have been used as a marker of
disease severity [20-23]; however, data indicate that a
large percentage of patients who suffer from extreme
pain never go to the hospital [24-26].
Nevertheless, adult sickle cell providers seeing a pa-
tient for the first time ask that patient a set of questions
to gauge the severity of his or her disease. Blood transfu-
sions and daily use of pain medicine are types of health
care utilization associated with severity of SCD. Compli-
cations of SCD include asplenia, retinopathy, avascular
necrosis, leg ulcers, kidney disease, stroke, and pulmon-
ary hypertension. A medical history characterized by
prescription pain medication, blood transfusions and a
number of these diagnoses in a patient presenting with
SCD could indicate severe disease [27-32]. In the ab-
sence of a consensus method for determining severity,
we reasoned that a method which mimicked the clinical
interview in content would identify patients who differed
in the amount of SCD-related damage caused by their
sickle cell and this could serve as a surrogate marker of
disease severity.
Following the logic outlined above, we included a
checklist of seven conditions usually secondary to SCD
and two treatments indicative of severity as part of the
data collection. For convenience, we refer to this indica-
tor here as the SCD Medical History Checklist (SCD-Table 1 ASCQ-Me item sets (Health topics) and example ques
Topic Example question
Cognitive Impact In the past 7 days, how often did you have
Emotional Impact In the past 7 days, how often were you ve
Physical Impact In the past 7 days, how often were your jo
Social Impact In the past 30 days, how much did your he
Pain Episodes Using any number from 0 to 10, where 0 i
during your last pain attack (crisis)?MHC). Along with the checklist, we included 10 global
health items from the PROMIS®, and 12 comorbidity
checklist questions unrelated to SCD taken from the
PROMIS® comorbidity questions (e.g. diabetes, pregnancy,
hepatitis-C, HIV/Aids). We expected the SCD-MHC to be
related to the PROMIS® globals as well as reported health
care utilization and pain episodes; but, not to be related to
the PROMIS® comorbidity questions which referred to
conditions not associated with SCD.
Data collection procedure
Patients signed a consent form after they arrived at one
of seven geographically-dispersed sites of care participat-
ing in the ASCQ-Me field test. They were then seated at
a computer and a site coordinator helped them to log
onto the ASCQ-Me website. The coordinator then en-
tered the SCD type of the respondent and assisted the
respondent in reviewing a tutorial that demonstrated
how to operate the mouse, select responses to questions,
monitor progress toward completion, and take a break.
Respondents proceeded to complete the survey on their
own following the tutorial. The survey took about 55 mi-
nutes to complete on average. Respondents received an
honorarium for their participation.
Analytic methods
Prior to applying statistical models to the data, we evalu-
ated data quality by calculating the percent of missing
data for each question and flagging participants who
responded in less than one second to any question (on
the assumption that they were not reading the questions,
see van der Linden & Krimpen-Stoop, 2003 [33]). We
also evaluated the plausibility of the SCD-MHC as a
measure of severity by examining its relationship to sev-
eral variables which would be expected to be related to
differences in health based on previous research includ-
ing age, frequency and severity of vaso-occlusive epi-
sodes, frequency of emergency room visits, and the
PROMIS® global ratings of health. The SCD-MHC was
scored as the sum of the questions that were endorsed
as has been the method employed in previous research
with such checklists [33-36], and supported by research
showing negligible differences between unit and alternative
weighting methods for the scoring of checklists [37,38].tions
trouble remembering things people had just told you?
ry worried about needing to go to the hospital?
ints very stiff during the day?
alth make it hard for you to do things with your friends?
s no pain and 10 is the worst imaginable pain, how severe was your pain
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Within each of the four item sets (i.e., cognitive impact,
emotional impact, physical impact, and social function-
ing impact), we conducted confirmatory factor analysis
(CFA) using structural equation modeling (SEM) and
followed common current practice with regard to indi-
cations of model fit [39,40]. We conducted exploratory
factor analysis (EFA), with oblique rotation and identi-
fied the number of factors on the basis of a conver-
gence among criteria such as the results of parallel
analysis (PA) [41], a scree plot of the eigen values [42],
number of factors required to explain the majority of
the variance, and the simplicity of the factor pattern
[43]. All factor analyses were conducted on polychoric
correlation matrices and used maximum likelihood
estimation.
Multi-trait scaling analysis
The Multi-trait Analysis Program, [44,45] was used to:
(1) calculate the correlation of an item with its scale,
correcting for overlap [46], (2) compare that correlation
to its correlation with all other scales in the analysis; (3)
estimate the internal consistency reliability coefficients
for each hypothesized scale; and (4) calculate the per-
centage of respondents with the highest and lowest
scores possible, respectively, on each scale.
Evaluation of unidimensionality
Most health question sets exhibit a certain amount of
multidimensionality due to repeated use of common
phrases within the question stem (e.g. “how many” or
“how much”) or to content balancing within the health
domain (e.g. including items targeting attention and
memory within the cognitive functioning domain). Fol-
lowing Reise et al. (2007) [47], we considered an item set
to be essentially unidimensional if any identified multidi-
mensionality did not have consequences for the inter-
pretation of the underlying concept (i.e. did not
consequentially affect the relationship of items to theta)
by conducting bi-factor analysis. We specified two
models of the relationship of items to latent trait(s) but
used Item Response Theory (IRT) Graded Response
Models (GRMs) [48] instead of the SEM approach used
by Reise and colleagues [47]. The unidimensional models
specified a single latent trait and no correlated errors;
whereas, each item was allowed to have a discrimination
parameter on the general factor and one of the group
factors (identified earlier by the parallel analysis and
EFA) in the bi-factor model specification. Both the uni-
dimensional and bi-factor IRT models were fitted using
the IRT-PRO software [49]. As this was new software,
we confirmed all analyses by conducting unidimensional
and bi-factor CFA’s using the SAS CALIS procedure. Es-
sential unidimensionality was supported if the Pearsoncorrelation between the vectors of discrimination param-
eters under the unidimensional model and the bi-factor
model was high (e.g. > 0.90) and the root mean squared
difference of discrimination parameters between the two
models was comparatively low [50].
Item-level measurement bias
In an IRT framework, an item is defined as displaying
measurement bias (i.e., differential item functioning) if
the item response curves (i.e., item parameters) are not
the same for the reference and focal group [51]. We im-
plemented a rank-based strategy as proposed by Woods
[52] to select anchor items, followed by the IRT-based
Wald test method [53-55] (denoted here as IRT-Wald),
to detect differential item functioning (DIF) for each
item. The sample was homogenous with regard to race
and the education level of respondents exceeded the
question vocabulary (6th grade level) so we did not
evaluate DIF due to race or education; but we did evalu-
ate DIF for age and gender.
IRT calibration
We fit the GRM to estimate discrimination and location
parameters for each item (using the marginal maximum
likelihood method [56]) which, respectively, describe the
strength of the item’s relationship to the latent trait and
the position of the item on the trait continuum; and, to-
gether, determine the information function of the item.
Validity
Evidence for the content validity of items and measures
was provided by the GIT [7] and review of legacy mea-
sures [6]. The validity of each item as a measure of the
underlying health domain was evaluated via CFA. In
addition, we determined the ability of each measure to




At a total of 561 respondents, we exceeded our targeted
number of 550 patients by 11. ASCQ-Me field test
participants represented a range of ages and a mix of
gender and genotype (see Table 2). During the past
12 months, one in five respondents reported two or
more sickle cell related pain episodes and the majority
indicated considerable suffering during these episodes.
On a scale of 0 to 10 where 0 was no pain and 10 was
the worst pain imaginable, the average rating was 8 and
nearly 30% indicated that the pain was the “worst pain
imaginable”. When asked to rate interference from pain
during the last episode, 37% indicated needing help from
family or friends or constant care from family, friends or
health care providers. On the other hand, nearly one in




18 to 24 29%
25 to 34 33%
35 to 44 20%
45 to 54 11%
55 to 64 6%





Sickle Cell Anemia (SS) 64%
Sickle Hemoglobin C Disease (SC) 21%
Sickle Beta-Thalassemia Disease (Beta) 10%
Unspecified Sickle Cell Disease (Other) 5%
How much did your last pain attack (crisis) interfere
with your life?
I've never had a pain attack (crisis) 2%
Not at all, I did everything I usually do 10%
I had to cut down on some things I usually do 21%
I could not do most things I usually do 30%
I could not take care of myself…needed some help… 18%
I could not take care of myself and needed
constant care…
19%
About how long did your most recent pain attack
(crisis) last?
I've never had a pain attack (crisis) 2%
Less than 1 hour 4%
1 - 12 hours 18%
13 - 24 hours 8%
1 - 3 days 22%
4 - 7 days 25%
1 - 2 weeks 14%
More than 2 weeks 7%
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The majority of respondents indicated that their most re-
cent pain episode lasted more than a day, with nearly 50%
saying that it lasted more than the better part of a week,
and more than 20% suffered more than a week with their
latest attack.Data quality
None of the participants was flagged for responding too
quickly to the questions. Ten questions which addressed
work functioning had high rates of missing data (>200
respondents), because a large portion of respondents
were not employed. We were therefore not able to in-
clude these 10 questions in the analysis of the Social
Functioning Impact measure.
To evaluate the suitability of the SCD-MHC as an
index of SCD severity we examined its relationship to
several variables which are related to differences in
health including age [57], frequency and severity of
vaso-occlusive incidents [58,25], frequency of emergency
room visits [59,60] and the PROMIS® global ratings of
health [61]. Table 3 shows the results of a series of gen-
eral linear models in which the variables listed in the
row headings were regressed onto the SCD-MHC or the
checklist of 12 co-morbidities which are not secondary
to SCD (pulled from the PROMIS® co-morbidity check-
list). For convenience, we refer to the checklist of 12 co-
morbidities that are not associated with SCD as the
Non-SCD-MHC. The pattern of relationships described
in Table 3 supports the validity of the SCD-MHC as an
indicator of SCD severity for these patients because the
relationships to other indicators of health are highly sig-
nificant and consistent and cannot be explained on the
basis of common method bias. As shown in Table 3, the
SCD-MHC was related to four of five items measuring
the reported frequency and severity of vaso-occlusive
incidents, while the Non-SCD-MHC was significantly re-
lated to only one of five. The SCD-MHC was also sig-
nificantly related to age and number of emergency room
visits, while the Non-SCD-MHC was not. Finally, the re-
lationship of the SCD-MHC to general health as mea-
sured by the 10 PROMIS® Globals was far stronger and
more consistent than the relationship of the Non-SCD-
MHC index to the 10 PROMIS® Globals.Item bank construction
Unidimensionality
Although respondents were allowed to skip any of the
field test questions, only five respondents had to be
eliminated from the psychometric analysis due to miss-
ing data. This represented just one percent of the total
number of respondents. Thus the psychometric analysis
was conducted using 556 respondents. Item-total corre-
lations for the Physical Impact item set confirmed our
suspicion that the content of that bank would more ap-
propriately reside in three groups representing pain (17
items), stiffness (19 items) and sleep functioning (20
items). Going forward, we evaluated the pain, stiffness
and sleep functioning questions as three distinct item
sets. This resulted in six item sets in total. Items were
Table 3 Evaluation of the SCD-MHC as an indicator of SCD severity
Evaluation variables F-Stat
SCD-MHCǂ Non-SCD-MHC¥
What is your age? 47.07*** 00.17
Past 12 mos, how many times did you go to the ED because of a pain attack (crisis)? 12.03*** 03.00
Severity of Vaso-Occlusive Events 04.3* 00.80
Past 12 mos, how many sickle cell pain attacks (crises) did you have? 03.57 06.35**
When was your last pain attack (crisis)? 05.96* 00.27
Rate severity of pain in last attack 12.54*** 00.03
How much did your last pain attack (crisis) interfere with your life? 13.24*** 00.03
About how long did your most recent pain attack (crisis) last? 36.37*** 03.10
PROMIS Globals 31.99*** 02.29
In general, would you say your health is: 32.13*** 02.29
In general, would you say your quality of life is: 10.22** 07.36**
In general, how would you rate your physical health? 10.64*** 06.64**
In general, how would you rate your mental health, including your mood and your ability to think? 27.79*** 18.82***
…, how would you rate your satisfaction with your social activities and relationships? 31.91*** 07.80**
To what extent are you able to carry out your everyday physical activities? 6.59** 04.56*
Past 7 days, how would you rate your pain on average? 31.63*** 00.61
Past 7 days, how would you rate your fatigue on average? 03.07 10.13**
Past 7 days, please rate how well you carry out your usual social activities and roles 47.07*** 00.17
Past 7 days, how often … bothered by emotional problems such as…? 12.03*** 03.00
ǂSCD-MHC = Sickle Cell Disease Medical History Checklist.
¥Non-SCD-MHC = Checklist of medical history conditions not associated with Sickle Cell Disease.
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correlations (see Table 4, 1st column under "causes for
elimination").
EFA, restricted to the number of factors that emerged
in the PA, were conducted on the remaining items in
each question set to identify the simple structure pattern
that would be modeled by the IRT bi-factor analysis.
Items which did not conform to simple structure were
eliminated from four of six question sets (see Table 4,
2nd column under "causes for elimination"). The subse-
quent IRT analysis identified local dependence among
pairs of the remaining items in five of six question sets.
One item from each pair was deleted from the sets
(see Table 4, 3rd column under "causes for elimination").Table 4 Number of items eliminated and cause for eliminatio
Cause for elimination







A total of nine items from four of the question sets dem-
onstrated measurement bias with regard to age or gen-
der and so were eliminated (see Table 4, 4th column
under "causes for elimination" and Table 5). Table 5 lists
the items for which we found DIF due to gender or age
following the methods detailed above.
Reliability
Reliability statistics for ASCQ-Me are presented in the
first two columns after the row headings of Table 6
which show, respectively: (1) the range of scores (out of
a possible range of 6) wherein measurement error is
below the threshold that is associated with greater thann
ple structure violation Local dependence DIF Final # of items
3 5 0 15
1 0 2 20
0 4 0 13
0 4 2 12
1 3 4 17
1 2 1 15
Table 5 Items with biased measurement across genders or ages
Question set Gender bias Age bias
Emotional
… feel very good about your health?
… feel very hopeful about your health?
Sleep
… if you woke… how easy ….to fall back asleep?
… how easy …to fall asleep?
Social
…your family…worried about your health?
…health make it hard for you to go places?
…have to change the plans because of your health? …have to change the plans because of your health?
Stiffness … impossible for you to move…legs or arms
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underlying construct (based on information curves pro-
duced by the IRT 2-parameter GRM); and (2) Cronbach’s
alpha coefficient estimate of internal consistency reliability
[62]. The first column shows highly reliable measurement
in the range of 4–5 out of 6 of the possible score distribu-
tion. We do not expect highly reliable measurement in the
tails of the score range, by definition, as restricted range
decreases statistical power. The second column shows the
average reliability of scores for the measures to be well
above the recommended 0.90 for use at the individual-
patient level.
Validity
The third column of Table 6 displays statistics for bi-
factor models of the relationship of items to a single
underlying dimension with secondary dimensions mod-
eling artifactual covariances for each ASCQ-Me item
bank. All comparative fit indices (CFI’s) are above the
liberal criterion for good model fit (0.90) and three of six
are at or above the more conservative criterion of 0.95.Table 6 Reliability and validity of ASCQ-Me item banks
Question sets Score range






Cognitive Impact 3.7 0.95 0.9
Emotional Impact 4.1 0.96 0.9
Pain 4.0 0.95 0.9
Sleep Impact 4.1 0.92 0.9
Social Impact 4.8 0.95 0.9
Stiffness 4.4 0.95 0.9
§This is out of a total scale score range of 6 which includes those at the very top an
ψConfirmatory Factor Analysis was conducted using structural equation modeling in
influence of a single dimension and a number of group factors.
¥Comparative fit index (CFI) compares the variance explained by the model to the t
between the predicted and observed correlation matrix) to “1.0” (the predicted corr
ǂRoot Mean Square Error of Approximation (RMSEA) is the amount of variance that
*These are the correlations between the vector of discrimination parameters for the
(IRT GRM) which indicate the amount of agreement between the two models in the
**All F-statistics were significant at p < 0.0001 with the exception of that associatedWhile the root-mean-square error of approximation
(RMSEA) rates are higher than the range of 0.06-0.10 that
is typically recommended in psychometric texts, [39,63]
they are consistent with that reported in the literature for
other PRO measures of this type [64] and with findings re-
garding the relationship of fit indices to degrees of free-
dom [65].
The next to the last column in Table 6 shows the cor-
relations between the vectors of discrimination parame-
ters for the bi-factor and uni-factor IRT models exceed
0.95 in every case. This suggests that the secondary fac-
tors which were modeled, dealt with sources of variabil-
ity unrelated to the primary factor.
The last column in Table 6 displays additional evi-
dence for the validity of the ASCQ-Me measures. We
looked at the relationship of ASCQ-Me scores to the al-
ternative marker of SCD condition severity based on the
number of SCD sequelae and treatments endorsed from
a list of nine, total (that is, the SCD-MHC). We divided
respondents into tertiles based on the distribution of the




5 0.10 0.96 02.92
3 0.09 0.97 16.56
4 0.09 0.96 31.67
8 0.08 0.96 12.13
5 0.10 0.96 20.51
4 0.11 0.96 38.72
d bottom of the range.
which the responses to each question were modeled as comprised of the
otal amount of variance in the data. The CFA runs from “0” (no relationship
elation matrix is identical to the observed).
is not predicted by the model.
bi-factor with the uni-factor Item Response Theory Graded Response Model
relationship of items to the underlying construct.
with the cognitive functioning measure which was > 0.05.
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univariate analysis of variance models). The ASCQ-Me
scores for all measures with the exception of the cognitive
functioning measure, significantly differed according to
SCD severity level (p < 0.0001), such that those with the




We evaluated the reliability and validity of 140 questions
designed to provide data that could be used to measure
the patient-reported functioning and well-being of adults
with SCD by conducting psychometric analysis of data
from 556 patients. These patients, varying in age, gender,
SCD Type, and SCD severity, provided us with high-
quality responses to questions administered through the
internet in a range of clinical settings. We eliminated 48
questions that either did not form clean factors or pro-
vided biased measurement across subgroups defined by
age and gender. As a result, we derived six item banks
that measure cognitive, emotional and social function-
ing, sleep quality, pain and stiffness. These six measures,
collectively called ASCQ-Me, provide highly reliable
measurement according to IRT total information curves
as well as internal consistency reliability estimates. Ana-
lysis of construct validity supported the essential unidi-
mensionality of the item banks and the measures
discriminate among levels of disease severity defined on
the basis of medical history. With one exception, across
multiple criteria, we recommend the use of these item
banks to contribute to studies of the health of patients
with SCD. We do not recommend the use of the Cogni-
tive Impact measure at this time because, compared to
the other measures, it provided reliable measurement
across a more restricted score range and was far weaker
in discriminating among levels of severity in SCD.
The psychometric analyses detailed here were used to
identify a final set of questions which produce reliable
health outcome scores using far fewer than the 140
questions to which patients in the field test responded.
As shown in Table 4, the five recommended item banks
(absent the cognitive bank) include just 77 items, follow-
ing elimination of questions based on the psychometric
analysis. Moreover, the purpose of constructing the IRT-
calibrated item banks was to identify still smaller subsets
of items within each that can be used to provide precise
measurement for particular applications. IRT calibrations
indicate which items are most informative at a particular
level of the trait being measured and thus enable the
construction of short form measures. For example, we
have constructed reliable short form measures totaling
just 5 questions for each of the five recommended item
banks. This enables users to measure all five ASCQ-Meconcepts using just 25 questions. Moreover, IRT-
calibrated item banks such as those included in ASCQ-
Me can be administered using computer adaptive software
the purpose of which is an alternative way to produce reli-
able measurement with as few questions as possible. Such
software has been developed for ASCQ-Me.
Limitations
We were limited by the study design in the range of ana-
lyses we could do to address the validity of the item
banks. Data were collected at one point in time so we
could not address the relationship of ASCQ-Me scores
to change in condition. We had one clinical indicator of
disease and this is known to be a poor measure of sever-
ity. Previous research supports the validity of self-report
methods of multi-morbidity assessment, [66] and so we
put considerable thought and careful analysis into devel-
oping the self-reported medical history checklist (SCD-
MHC). We described the relationship of checklist scores
to other markers of health burden: age, utilization, pain
episode recency and severity, and PROMIS® global rat-
ings of health. Because they derive from the same
source, the relationship between SCD-MHC scores and
ASCQ-Me item bank scores might be artifacts of the
data collection method. This hypothesis was not sup-
ported because the ASCQ-Me scores did not have a
strong and consistent relationship to a comorbidity
index that was comprised of self-reported conditions
which are not characteristic of SCD (e.g. migraine, can-
cer, rheumatoid arthritis).
The respondents included a mix of ages, gender, and
disease type however those older than 54 (7%) and with
SCD Type other than SS were in the minority. This pre-
vented us from conducting psychometric analyses spe-
cific to patients with SC (21%) or Beta types (10%) or
who were older than middle aged.
We do not know how representative our field test
sample is because a nationally-representative, descriptive
study of the socio-demographic and health characteris-
tics (e.g. severity of disease, incidence of comorbid con-
ditions) of adults with SCD does not yet exist. Such a
study is hampered by the difficulty in developing a com-
prehensive sampling frame. That frame cannot rely on
medical records or registries alone because many adults
with SCD are not included in those data bases. More-
over, the stigma associated with SCD is a barrier to ac-
curately identifying the names and contact information
of individuals. However, this issue is not unique to the
current research and indeed applies to all research re-
sults involving adults with SCD which seek to generalize
to the population. Current scoring for the ASCQ-Me
item banks is relative to this field test sample so that a
score of 50 represents the average score for the 556 re-
spondents. Ideally, we would like to be able to say that
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adults with SCD. While we do not have a descriptive
study of adults with SCD, available data suggests that
the characteristics of our sample are likely to mirror those
of the other populations with regard to age of participat-
ing adults and hemoglobin type [67-69]. Adult males with
SCD may have been under-represented in our sample. Al-
though results have been mixed [70] female gender has
previously been associated with diminished health-related
quality of life in the physical domain [68] and reports of a
higher prevalence of pain episodes [6]. Our results should
therefore be viewed with caution, until such time as a
population-based description of socio-demographic and
health characteristics of the U.S. SCD population is
available.
Future research
Further analyses of the field test data will be conducted
to evaluate the potential of identifying cut-off scores for
the ASCQ-Me item banks and short forms. Such scores
could serve as interpretative aids which would enhance
the usefulness of the ASCQ-Me measures for clinical
practice.
While sample size prevented us from including the
work-functioning questions in the IRT analysis con-
ducted to develop ASCQ-Me, we intend to explore the
development of a static work functioning scale for adults
with SCD based on the field test items and data. Em-
ployment and work functioning were of great concern to
participants in our focus groups and these concerns fre-
quently surfaced as well in our individual interviews with
adult patients.
Finally, should resources become available, we intend
to collect longitudinal data with the ASCQ-Me measures
which would permit us to evaluate the sensitivity of
these measures to change over time. An ideal study
would be a placebo-controlled study in which the size of
the change in ASCQ-Me scores associated with the
introduction of a treatment of known efficacy was evalu-
ated. We are aware, also, of ongoing studies conducted
by other investigators in which ASCQ-Me data are being
collected longitudinally to evaluate the efficacy of drug
therapy and to evaluate the impact of differences in
health care delivery systems, and eagerly anticipate their
reports.
Conclusions
A valid measure of health outcome is required to inform
the design and delivery of health care for adults with
SCD. Building on a comprehensive program of formative
research and statistical analysis of field test data on more
than 550 patients, we applied advanced psychometric
methods including those currently used by the PROMIS®
initiative [10,71] to construct the ASCQ-Me measures ofCognitive, Emotional, Pain, Sleep, Social and Stiffness
Impact. Our results support the reliability and validity of
all measures, with the exception of Cognitive Impact,
and we encourage the use of the remaining five mea-
sures in future studies conducted by the broader re-
search community.
The contribution of research described herein was to
develop a system called ASCQ-Me to provide a standard
method for describing the life impact of SCD on adult
functioning and wellbeing which would enable the com-
parison of health outcomes for these patients across
medical, clinical and health services research on SCD.
Strengths of this research include: 1) roots in a rigorous
program of formative research with adults with SCD [6];
2) the participation of a large number of adults with
SCD in the field test (>550 patients), 3) the application
of advanced psychometric methods consistent with stan-
dards put forth by the PROMIS® initiative [10,71], 4) a
careful focus on evaluating and eliminating sources of
bias in measurement, 5) evaluation of the validity of the
ASCQ-Me measures using a measure of SCD severity
that does not suffer from the weaknesses of often-used
measures such as number of hospitalizations or SCD
type, and 6) the development of item banks which can
support the construction of short sets of questions for
each health concept suitable for administration via fixed
forms or adaptively, to provide precise measurement
with as few questions as possible. This system is cur-
rently in use in a number of studies which will provide
further information on the validity of the scores and the
usefulness of the system; including studies of the sensi-
tivity of ASCQ-Me scores to change in health that might
result from drug therapy or from changes in how health
care is delivered.
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